Regeneron Pharmaceuticals, Inc. functions as a global biopharmaceutical enterprise, concentrating its efforts on the research, creation, advancement, production, and global commercialization of medicinal treatments for a diverse array of human diseases. The company's robust catalog of approved therapies includes: EYLEA injection, indicated for various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema that develops after retinal vein occlusion (both central and branch types). Dupixent injection, prescribed for managing atopic dermatitis and asthma in both adults and children.